Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

EVOBREAST Uncovering immunoediting strategies underlying malignant transformation in breast tissues

Coordinator
Institute of Cancer Research: the Royal Cancer Hospital Lbg, United Kingdom
Runs
1 July 2025 to 30 June 2027
Status
Running
EU funding
€260k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101206099

What the project is doing

In the project's own words, from its summary on CORDIS.

Breast cancer is the leading cause of cancer-related death in women worldwide. Despite intense research that has led to improved clinical outcomes, a significant number of patients treated with standard therapies suffer from high toxicity and remain unresponsive. In parallel, Immune-Checkpoint Inhibitors (ICI) have transformed cancer treatment by unleashing patients' immune system to combat cancer cells through immunoediting, a natural evolutionary process of removal of antigenic tumor clones.

However, application of ICIs for breast cancer remains a challenge as we currently have limited knowledge of the immunoediting strategies and the mechanisms of immune evasion occurring in healthy and malignant tissues. We hypothesize that immunoediting shapes genetic heterogeneity and immunogenicity in healthy mammary cells, driving malignant transformation and response to clinical interventions. To test our hypothesis, we will investigate the mechanisms and influence of immune selection in mammary cells by exploiting novel genomic technologies, providing critical insight into the interplay between the immune system and breast cancer initiation.

Our research project will focus on (1) exploring immune selection in healthy and premalignant breast tissues, (2) characterising immune cell populations and their spatial distribution, and (3) determining which interactions prevail during tumour progression. To achieve these goals, we will employ a combination of advanced molecular and high-throughput technologies, including laser microdissection, whole exome sequencing, RNA sequencing, and spatial transcriptomics.

Our research has the potential to significantly advance our understanding of breast cancer occurrence and spread, ultimately leading to the development of novel prevention strategies, early detection methods, and personalised treatment approaches that harness the power of the immune system to fight more effectively breast tumorigenesis.

Topics

Who is involved

OrganisationCityCountryRole
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomCoordinator
University College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI